---
document_datetime: 2025-12-02 05:47:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/oxervate.html
document_name: oxervate.html
version: success
processing_time: 0.1116482
conversion_datetime: 2025-12-24 23:30:34.084958
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Oxervate

[RSS](/en/individual-human-medicine.xml/66090)

##### Authorised

This medicine is authorised for use in the European Union

cenegermin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Oxervate](#news-on)
- [More information on Oxervate](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Oxervate. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Oxervate.

For practical information about using Oxervate, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Oxervate and what is it used for?

Oxervate is a medicine used to treat neurotrophic keratitis, an eye condition in which damage to the trigeminal nerve supplying the surface of the eye causes loss of sensation and defects that do not heal naturally.

The medicine is only used in adults with moderate or severe disease.

Because the number of patients with neurotrophic keratitis is low, the disease is considered 'rare', and Oxervate was designated an 'orphan medicine' (a medicine used in rare diseases) on 14 December 2015.

Oxervate contains the active substance cenegermin.

## How is Oxervate used?

Oxervate is available as eye drops. The recommended dose is 1 drop in the affected eye every 2 hours, 6 times per day. Treatment should continue for 8 weeks.

Oxervate can only be obtained with a prescription and treatment should be started and supervised by an eye specialist.

For further information, see the package leaflet.

## How does Oxervate work?

Patients with neurotrophic keratitis have lower than normal levels of substances including growth factors that are normally supplied by the trigeminal nerve and which play an important role in the growth and survival of the cells of the eye's surface. The active substance in Oxervate, cenegermin, is a copy of a human growth factor called nerve growth factor. When given as eye drops to patients with neurotrophic keratitis, cenegermin helps restore some of the normal healing processes in the eye and repair damage to the eye's surface associated with the condition.

## What benefits of Oxervate have been shown in studies?

Oxervate has been shown to help heal damage to the eye's surface in 2 main studies involving a total of 204 adults with moderate or severe neurotrophic keratitis. In the first study, 74% (37 out of 50) of patients treated with Oxervate for 8 weeks achieved complete healing of the eye's surface compared with 43% (22 out of 51) of patients treated with a dummy treatment containing the same eye drop formula but no active substance. In the second study, figures were 70% (16 out of 23) with Oxervate and 29% (7 out of 24) with the dummy treatment.

## What are the risks associated with Oxervate?

The most common side effects with Oxervate (which may affect more than 1 in 100 people) are eye pain and inflammation, increased lacrimation (watery eyes), pain in the eyelid and sensation of a foreign body in the eye.

For the full list of all side effects and restrictions with Oxervate, see the package leaflet.

## Why is Oxervate approved?

Oxervate has been shown to increase by around 30-40% the number of patients who achieve complete healing of the eye's surface when compared with eye drops containing no active substance. Side effects with Oxervate are mainly related to the eye, are mild or moderate in severity and resolve over time.

The European Medicines Agency therefore decided that Oxervate's benefits are greater than its risks and recommended that it be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Oxervate?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Oxervate have been included in the summary of product characteristics and the package leaflet.

## Other information

The European Commission granted a marketing authorisation valid throughout the European Union for Oxervate on 06 July 2017. For more information about treatment with Oxervate, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Oxervate : EPAR - Summary for the public

English (EN) (75.24 KB - PDF)

**First published:** 25/07/2017

**Last updated:** 25/07/2017

[View](/en/documents/overview/oxervate-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-789)

български (BG) (99.79 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/bg/documents/overview/oxervate-epar-summary-public_bg.pdf)

español (ES) (74.52 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/es/documents/overview/oxervate-epar-summary-public_es.pdf)

čeština (CS) (99.27 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/cs/documents/overview/oxervate-epar-summary-public_cs.pdf)

dansk (DA) (74.03 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/da/documents/overview/oxervate-epar-summary-public_da.pdf)

Deutsch (DE) (75.14 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/de/documents/overview/oxervate-epar-summary-public_de.pdf)

eesti keel (ET) (72.38 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/et/documents/overview/oxervate-epar-summary-public_et.pdf)

ελληνικά (EL) (100.73 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/el/documents/overview/oxervate-epar-summary-public_el.pdf)

français (FR) (74.96 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/fr/documents/overview/oxervate-epar-summary-public_fr.pdf)

hrvatski (HR) (93.13 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/hr/documents/overview/oxervate-epar-summary-public_hr.pdf)

italiano (IT) (73.88 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/it/documents/overview/oxervate-epar-summary-public_it.pdf)

latviešu valoda (LV) (95.52 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/lv/documents/overview/oxervate-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (97.21 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/lt/documents/overview/oxervate-epar-summary-public_lt.pdf)

magyar (HU) (94.54 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/hu/documents/overview/oxervate-epar-summary-public_hu.pdf)

Malti (MT) (140.66 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/mt/documents/overview/oxervate-epar-summary-public_mt.pdf)

Nederlands (NL) (74.28 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/nl/documents/overview/oxervate-epar-summary-public_nl.pdf)

polski (PL) (100.05 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/pl/documents/overview/oxervate-epar-summary-public_pl.pdf)

português (PT) (74.47 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/pt/documents/overview/oxervate-epar-summary-public_pt.pdf)

română (RO) (96.09 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/ro/documents/overview/oxervate-epar-summary-public_ro.pdf)

slovenčina (SK) (96.88 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/sk/documents/overview/oxervate-epar-summary-public_sk.pdf)

slovenščina (SL) (91.88 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/sl/documents/overview/oxervate-epar-summary-public_sl.pdf)

Suomi (FI) (72.73 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/fi/documents/overview/oxervate-epar-summary-public_fi.pdf)

svenska (SV) (73.05 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/sv/documents/overview/oxervate-epar-summary-public_sv.pdf)

Oxervate : EPAR - Risk management plan summary

English (EN) (107.79 KB - PDF)

**First published:** 04/04/2022

[View](/en/documents/rmp-summary/oxervate-epar-risk-management-plan-summary_en.pdf)

## Product information

Oxervate : EPAR - Product Information

English (EN) (346.89 KB - PDF)

**First published:** 25/07/2017

**Last updated:** 25/10/2024

[View](/en/documents/product-information/oxervate-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-261)

български (BG) (582.78 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/bg/documents/product-information/oxervate-epar-product-information_bg.pdf)

español (ES) (553.53 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/es/documents/product-information/oxervate-epar-product-information_es.pdf)

čeština (CS) (728.61 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/cs/documents/product-information/oxervate-epar-product-information_cs.pdf)

dansk (DA) (540.75 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/da/documents/product-information/oxervate-epar-product-information_da.pdf)

Deutsch (DE) (531.66 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/de/documents/product-information/oxervate-epar-product-information_de.pdf)

eesti keel (ET) (402.76 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/et/documents/product-information/oxervate-epar-product-information_et.pdf)

ελληνικά (EL) (572.84 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/el/documents/product-information/oxervate-epar-product-information_el.pdf)

français (FR) (667.07 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/fr/documents/product-information/oxervate-epar-product-information_fr.pdf)

hrvatski (HR) (609.56 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/hr/documents/product-information/oxervate-epar-product-information_hr.pdf)

íslenska (IS) (632.7 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/is/documents/product-information/oxervate-epar-product-information_is.pdf)

italiano (IT) (916.48 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/it/documents/product-information/oxervate-epar-product-information_it.pdf)

latviešu valoda (LV) (642.45 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/lv/documents/product-information/oxervate-epar-product-information_lv.pdf)

lietuvių kalba (LT) (533.14 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/lt/documents/product-information/oxervate-epar-product-information_lt.pdf)

magyar (HU) (597.62 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/hu/documents/product-information/oxervate-epar-product-information_hu.pdf)

Malti (MT) (774.43 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/mt/documents/product-information/oxervate-epar-product-information_mt.pdf)

Nederlands (NL) (485.83 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/nl/documents/product-information/oxervate-epar-product-information_nl.pdf)

norsk (NO) (570.18 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/no/documents/product-information/oxervate-epar-product-information_no.pdf)

polski (PL) (588.86 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/pl/documents/product-information/oxervate-epar-product-information_pl.pdf)

português (PT) (590.07 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/pt/documents/product-information/oxervate-epar-product-information_pt.pdf)

română (RO) (721.49 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/ro/documents/product-information/oxervate-epar-product-information_ro.pdf)

slovenčina (SK) (619.72 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/sk/documents/product-information/oxervate-epar-product-information_sk.pdf)

slovenščina (SL) (552.36 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/sl/documents/product-information/oxervate-epar-product-information_sl.pdf)

Suomi (FI) (620.16 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/fi/documents/product-information/oxervate-epar-product-information_fi.pdf)

svenska (SV) (524.07 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/10/2024

[View](/sv/documents/product-information/oxervate-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0064 23/10/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Oxervate : EPAR - All Authorised presentations

English (EN) (12.57 KB - PDF)

**First published:** 25/07/2017

**Last updated:** 25/07/2017

[View](/en/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-747)

български (BG) (34.91 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/bg/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_bg.pdf)

español (ES) (11.51 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/es/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_es.pdf)

čeština (CS) (23.22 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/cs/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (34 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/da/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (34.35 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/de/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (9.88 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/et/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (41.21 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/el/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_el.pdf)

français (FR) (10.65 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/fr/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (40.25 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/hr/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (33.02 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/is/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_is.pdf)

italiano (IT) (9.97 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/it/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (24.23 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/lv/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (39.17 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/lt/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (29.26 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/hu/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (24.45 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/mt/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (11.7 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/nl/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (33.97 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/no/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_no.pdf)

polski (PL) (23.3 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/pl/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_pl.pdf)

português (PT) (12.08 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/pt/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_pt.pdf)

română (RO) (38.88 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/ro/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (23.09 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/sk/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (22.73 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/sl/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (9.62 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/fi/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (32.23 KB - PDF)

**First published:**

25/07/2017

**Last updated:**

25/07/2017

[View](/sv/documents/all-authorised-presentations/oxervate-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Oxervate Active substance recombinant human nerve growth factor International non-proprietary name (INN) or common name cenegermin Therapeutic area (MeSH) Keratitis Anatomical therapeutic chemical (ATC) code S01

### Pharmacotherapeutic group

Ophthalmologicals

### Therapeutic indication

Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults

## Authorisation details

EMA product number EMEA/H/C/004209

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Dompe' Farmaceutici S.p.A.

Via San Martino 12 20122 Milano Italy

Opinion adopted 18/05/2017 Marketing authorisation issued 06/07/2017 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Oxervate : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (162.38 KB - PDF)

**First published:** 04/04/2022

**Last updated:** 25/10/2024

[View](/en/documents/procedural-steps-after/oxervate-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Oxervate-H-C-PSUSA-00010624-202207 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/146953/2023

English (EN) (161.74 KB - PDF)

**First published:** 02/06/2023

[View](/en/documents/scientific-conclusion/oxervate-h-c-psusa-00010624-202207-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Oxervate : EPAR - Public assessment report

Reference Number: EMA/351805/2017

English (EN) (1.87 MB - PDF)

**First published:** 25/07/2017

**Last updated:** 25/07/2017

[View](/en/documents/assessment-report/oxervate-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Oxervate

Adopted

Reference Number: EMA/CHMP/297602/2017

English (EN) (105.37 KB - PDF)

**First published:** 19/05/2017

**Last updated:** 19/05/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-oxervate_en.pdf)

#### News on Oxervate

[New medicine for rare eye disease](/en/news/new-medicine-rare-eye-disease) 19/05/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 May 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-may-2017) 19/05/2017

#### More information on Oxervate

- [EU/3/15/1586 - orphan designation for treatment of neurotrophic keratitis](/en/medicines/human/orphan-designations/eu-3-15-1586)
- [EMEA-001729-PIP02-18 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001729-pip02-18)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 25/10/2024

## Share this page

[Back to top](#main-content)